SHL Medical

Executive Summary

SHL Medical is a global leader in the design and manufacture of advanced self-injection devices, including autoinjectors and pen injectors. Founded in 1989 and headquartered in Zug, Switzerland, the company provides end-to-end solutions from device development to final assembly and packaging for pharmaceutical and biotechnology partners. With a strong focus on improving patient independence and treatment outcomes, SHL Medical has established itself as a key partner in the growing self-injection market, driven by the rise of biologics and chronic disease therapies. The company operates globally with significant R&D and manufacturing capabilities, particularly in Sweden and Switzerland, and continues to invest in capacity expansion and technological innovation to meet increasing demand. As a private entity, SHL Medical does not disclose financial details, but its strong market position and strategic partnerships underpin its long-term growth prospects.

Upcoming Catalysts (preview)

• TBDNew partnership with a top-20 pharma for a blockbuster biologic device70% success
• Q3 2026Announcement of manufacturing capacity expansion (e.g., new facility in US or Europe)80% success
• TBDLaunch of next-generation connected autoinjector platform with digital health features60% success